CUAJ, Editor. Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients with Urological Cancers – Adverse Events (AEs): Management Tool Kit. Canadian Urological Association Journal, [S. l.], v. 15, n. 1X, 2026. Disponível em: https://cuaj.ca/index.php/journal/article/view/9883. Acesso em: 31 may. 2026.